Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Chromosomal Disorder
Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Chromosomal Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Guanfacine Maimonides Medical Center | Phase 4 | BB |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Rituximab Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Melphalan Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →